Review the patient's case. Are there no genetic tests or biomarkers in any of the documents

Genetic Tests and Biomarkers in Hillel Bierbrier's Case

Actually, there are important genetic findings documented in this case. According to the clinical summary, the following biomarkers and genetic tests have been identified:

Genetic Mutations Found:

1. BRCA2 Positive Mutation - This is a significant finding that affects DNA repair and can influence treatment options

2. Non-classical Heterozygous ATM Mutation - This is a variation in the ATM gene (also involved in DNA repair)

Tumor Characteristics (Biomarkers):

The pathology also documents:

• Poorly differentiated squamous cell carcinoma - This describes how abnormal the cancer cells appear under the microscope
• Specific invasion patterns - The cancer has invaded into the submucosa (tissue layer beneath the surface) and smooth muscle fibers

Clinical Significance:

The document specifically recommends "Genetic Counseling: Follow-up on BRCA2+ and ATM mutations for treatment implications and family screening" as part of the provider recommendations.

These genetic findings are important because they may influence:

• Which treatments might be most effective
• Whether certain targeted therapies could be considered
• Family members' screening needs

Given the disease progression after initial chemoradiation, these genetic markers should be discussed with the oncology team, as they may open additional treatment options for recurrent anal cancer.